newsfilter
← Latest News
PR Newswire·

Independent Data Safety Monitoring Board Recommends Appili Therapeutics Complete Its Phase 3 Avigan®/Reeqonus™ Trial for Mild-to-Moderate COVID-19 Patients

HALIFAX, NS, May 17, 2021 /PRNewswire/ -- Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, today announced that an independent Data and Safety